Media headlines about Inovio Pharmaceuticals (NASDAQ:INO) have been trending somewhat positive this week, according to Accern. Accern rates the sentiment of media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Inovio Pharmaceuticals earned a news impact score of 0.07 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 47.2267558170087 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the headlines that may have impacted Accern Sentiment Analysis’s rankings:
- Inovio Pharmaceuticals, Inc. (INO) trend is considered bullish as stock price is 12.47% rising from 50 SMA – Analyst Recommendation (press release) (blog) (analystrecommendation.com)
- Inovio Pharmaceuticals, Inc. (INO) Noteworthy Price Swings – The Stocks News (press release) (thestocksnews.com)
- Hot Stock under Review – Inovio Pharmaceuticals, Inc. (NASDAQ: INO) – The Investor Guide (wallstreetnews24.com)
- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) – Here’s What Day Traders Should Know – Nasdaq Journal (nasdaqjournal.com)
- Is Stock’s Performance Impressive? – Inovio Pharmaceuticals Inc (NASDAQ: INO) – Alpha Beta Stock (alphabetastock.com)
Several equities analysts recently issued reports on the stock. Maxim Group decreased their target price on shares of Inovio Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a research note on Thursday, February 15th. HC Wainwright set a $13.00 target price on shares of Inovio Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, February 13th. Zacks Investment Research upgraded shares of Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, January 9th. Finally, BidaskClub upgraded shares of Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, March 14th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have issued a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $19.07.
Inovio Pharmaceuticals (NASDAQ:INO) last posted its quarterly earnings data on Wednesday, March 14th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.30) by $0.06. The company had revenue of $8.80 million during the quarter, compared to analysts’ expectations of $9.13 million. Inovio Pharmaceuticals had a negative net margin of 208.92% and a negative return on equity of 66.07%. The firm’s revenue for the quarter was up 3.5% on a year-over-year basis. During the same period in the prior year, the business posted ($0.35) earnings per share. sell-side analysts forecast that Inovio Pharmaceuticals will post -1.07 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Affect Inovio Pharmaceuticals (INO) Share Price” was originally reported by BBNS and is owned by of BBNS. If you are viewing this piece on another site, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The correct version of this piece can be viewed at https://baseballnewssource.com/2018/03/21/inovio-pharmaceuticals-ino-earning-somewhat-favorable-news-coverage-report-finds/1923978.html.
Inovio Pharmaceuticals Company Profile
Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.
Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.